1 October, 2014. Biotecnol announces that has appointed key experts to its Inaugural Medical and Scientific Advisory Board (MSAB). The chosen experts will advise the company on its translational pre-clinical activities as well as on the clinical development strategy of the Tribody™ programmes and will provide and overall strategic vision and focus of the same. The MSAB will be growing as the company develops as other key opinion leaders will be joining the company in order to support the execution of its vision, which consists on the development of best and first in-class immuno-oncology therapies.
About the Tribody™ format
Tribody™ molecules are multi-specific antibodies, produced by established recombinant DNA technology methods, which utilize the natural in vivo heterodimerization of Fab fragments to form a scaffold, upon which additional functionality can be incorporated. As a result Tribodies are characterized by an unsurpassed versatility; they can incorporate up to three different binding sites and can combine different functions, such as the ability to engage and redirect potent immune-effector cells like T-cells or NK-cells whilst retaining the ability to target more than one epitope in a tumor target, or more than one target in the same tumor, all in one single molecule.
Biotecnol is an immune-oncology company with a strong track-record in antibody drug development. The company has a proprietary antibody format -Tribody™- for engaging various immunological effector functions including T-cells, to destroy cancer cells. The Company is looking to strengthen this solid asset base of new agents in the immune-oncology field, by developing candidates with a dual approach involving novel targets. Biotecnol has fully integrated capabilities that allow the company to run and effectively manage its own drug development programmes, right from the antibody selection process to clinic proof of concept.Back to news